financetom
Business
financetom
/
Business
/
Looking At Johnson & Johnson's Recent Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking At Johnson & Johnson's Recent Unusual Options Activity
Oct 14, 2025 12:32 PM

Financial giants have made a conspicuous bearish move on Johnson & Johnson ( JNJ ). Our analysis of options history for Johnson & Johnson ( JNJ ) revealed 25 unusual trades.

Delving into the details, we found 24% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $757,641, and 15 were calls, valued at $1,152,391.

Predicted Price Range

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $165.0 to $220.0 for Johnson & Johnson ( JNJ ) during the past quarter.

Volume & Open Interest Development

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson & Johnson's ( JNJ ) options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson & Johnson's ( JNJ ) substantial trades, within a strike price spectrum from $165.0 to $220.0 over the preceding 30 days.

Johnson & Johnson 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
JNJ CALL SWEEP BEARISH 10/17/25 $8.45 $8.35 $8.35 $180.00 $212.8K 9.1K 1.0K
JNJ CALL SWEEP BEARISH 10/17/25 $8.5 $8.25 $8.25 $180.00 $207.9K 9.1K 828
JNJ PUT SWEEP BULLISH 04/17/26 $15.95 $15.9 $15.9 $200.00 $182.8K 31 106
JNJ CALL TRADE NEUTRAL 06/18/26 $30.85 $28.8 $29.9 $165.00 $179.4K 1.4K 60
JNJ CALL SWEEP BULLISH 10/17/25 $1.0 $0.81 $1.0 $192.50 $133.9K 6.0K 1.9K

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

After a thorough review of the options trading surrounding Johnson & Johnson ( JNJ ), we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Where Is Johnson & Johnson Standing Right Now?

With a volume of 8,802,438, the price of JNJ is down -0.48% at $189.99.

RSI indicators hint that the underlying stock may be overbought.

Next earnings are expected to be released in 0 days.

Expert Opinions on Johnson & Johnson

5 market experts have recently issued ratings for this stock, with a consensus target price of $206.2.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.

* Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Johnson & Johnson ( JNJ ), targeting a price of $200.

* An analyst from Citigroup persists with their Buy rating on Johnson & Johnson ( JNJ ), maintaining a target price of $213.

* An analyst from Guggenheim has elevated its stance to Buy, setting a new price target at $206.

* An analyst from UBS persists with their Buy rating on Johnson & Johnson ( JNJ ), maintaining a target price of $214.

* An analyst from B of A Securities persists with their Neutral rating on Johnson & Johnson ( JNJ ), maintaining a target price of $198.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Johnson & Johnson ( JNJ ), Benzinga Pro gives you real-time options trades alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen, Eisai Submit Supplemental Biologics License Application to FDA for Weekly Lecanemab Injections
Biogen, Eisai Submit Supplemental Biologics License Application to FDA for Weekly Lecanemab Injections
Nov 25, 2025
08:24 AM EST, 11/25/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Tuesday Eisai has completed the rolling submission of a supplemental Biologics License Application to the US Food and Drug Administration seeking approval for a weekly subcutaneous starting dose of lecanemab-irmb. The companies said the treatment is approved for Alzheimer's patients in the mild cognitive impairment or mild dementia...
New Generation Consumer Group Provides Corporate Update as Due Diligence Advances on Spiritual Glow Acquisition
New Generation Consumer Group Provides Corporate Update as Due Diligence Advances on Spiritual Glow Acquisition
Nov 25, 2025
PHOENIX, AZ / ACCESS Newswire / November 25, 2025 / New Generation Consumer Group, Inc. ( NGCG ) today issued a corporate update as the Company continues moving through the due diligence phase related to the proposed acquisition of a 51% controlling interest in the Spiritual Glow digital brand. Management reports that the development team is actively expanding NGCG's existing...
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
Nov 25, 2025
Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( LIXT ) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe...
Ondas to Acquire Roboteam, Expanding Market Footprint and Multi-Domain Autonomy with Field-Proven Tactical Ground Robotics
Ondas to Acquire Roboteam, Expanding Market Footprint and Multi-Domain Autonomy with Field-Proven Tactical Ground Robotics
Nov 25, 2025
Expands OAS's mission portfolio with Roboteam's rugged, multi-mission tactical ground robotics deployed by leading global defense customers Roboteam's established deployments with leading militaries across 30 countries expected to provide Ondas ( ONDS ) with a mature pipeline and accelerated access to priority defense programs Ondas ( ONDS ) expects Roboteam to add $3 - 4 million in revenue in Q4...
Copyright 2023-2026 - www.financetom.com All Rights Reserved